Obstructive sleep apnea (OSA) is characterized by intermittent hypoxia due to repetitive cessation of airflow during sleep. 1 In a general Western population, its prevalence is 5% to 15% and has a tendency to rise. 1 Its prevalence is even higher in patients with cardiovascular (CV) disease (30%-50%). [2] [3] [4] Patients with OSA frequently exhibit vascular risk factors, inflammation, and CV morbidity. [5] [6] [7] [8] Obstructive sleep apnea is associated with insulin resistance and impaired glucose metabolism, from a mild increase in glycated hemoglobin to overt type 2 diabetes mellitus (T2DM). [9] [10] [11] [12] In adults with T2DM, the frequency of OSA is markedly increased. 13 Diabetic polyneuropathy (DPN) is a common chronic complication of diabetes. 14 Its main feature is sensory loss in the distal lower extremities, while severe neuropathic pain may also be present. 14, 15 Diabetic polyneuropathy is the cardinal risk factor of diabetic foot ulceration mediated by unrecognized acute or chronic trauma. 16 Interestingly, there is now ample evidence that DPN is associated with CV risk factors and microangiopathy. 14, [17] [18] [19] Lately, there has been evidence that OSA is associated with DPN. 20, 21 Tahrani et al 20 have reported a significantly (P < .001) higher frequency of DPN in patients having T2DM with OSA. There was an independent association of DPN with OSA, with odds ratio (OR) ¼ 2.82 (95% confidence interval [CI]: 1.44-5.52, P ¼ .0034). 20 In this study, increased oxidative stress and impaired microcirculation encountered in patients with OSA were proposed as mechanisms underlying concomitant DPN. 20 Moreover, a meta-analysis has demonstrated an OR of 1.95 (95% CI: 1.03-3.70) in diabetic patients with DPN versus those without DPN. 21 In the light of this new knowledge, it is conceivable that OSA may contribute to the development of diabetic foot ulceration via DPN. Of note, patients with OSA are frequently obese, 1, 4 and obesity is known to increase plantar pressures, thus contributing to the risk of foot ulceration. 16 A very recent small case series 22 has shown that undiagnosed or inadequately treated severe OSA may be implicated in failure to achieve healing of foot ulcers. Impressively, continuous positive airway pressure therapy (CPAP), the standard treatment for OSA, was successful in accelerating wound healing. 22 The limitations of this work include the very small number (n ¼ 3) of patients, the presence of particularly severe OSA, and the paucity of data on neuropathy. However, this series is important in pointing to a potential role of OSA in failure to achieve ulcer healing in the absence of peripheral arterial disease or infection. 22 Taken together, available data suggest an emerging role of OSA in diabetic foot ulcers. First, OSA may, in theory, contribute to ulcer development through increased DPN and obesity. 1, 20, 21 Second, preliminary results indicate a potential role of OSA in delayed ulcer healing. 22 Third, CPAP treatment may improve ulcer outcomes. 22 Therefore, it may prove worthwhile to encourage clinicians to look for OSA in patients with nonhealing foot ulcers or in those at risk of future foot ulceration. In case OSA is diagnosed, CPAP appears promising, but it should be remembered to ensure patient compliance with this therapeutic modality. 23, 24 In conclusion, there is preliminary evidence on the importance of OSA for diabetic foot ulcers. Obstructive sleep apnea may delay ulcer healing, while it also has the potential to contribute to the development of diabetic foot lesions. In a multiexpert endeavor to save diabetic feet, 25 the management of OSA may eventually prove to be a new target to consider.
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